Adaptive pathways and emerging strategies overcoming treatment resistance in castration resistant prostate cancer.

ABSTRACT: The therapies available for prostate cancer patients whom progress from hormone-sensitive to castration resistant prostate cancer include both systemic drugs, including docetaxel and cabazitaxel, and drugs that inhibit androgen signaling such as enzalutamide and abiraterone. Unfortunately, it is estimated that up to 30% of patients have primary resistance to these treatments and over time even those who initially respond to therapy will eventually develop resistance and their disease will continue to progress regardless of the presence of the drug. Determining the mechanisms involved in the development of resistance to these therapies has been the area of intense study and several adaptive pathways have been uncovered. Androgen receptor (AR) mutations, expression of AR-V7 (or other constit

SUBMITTER: Armstrong CM 

PROVIDER: S-EPMC5477778 | biostudies-literature | 2016 Oct

REPOSITORIES: biostudies-literature